BioMarin Pharmaceutical Inc. develops enzyme therapies for serious chronic genetic disorders and other diseases and conditions. Its leading product, Aldurazyme, is used for treating the ultra-rare genetic disorder mucopolysaccharidosis-I (MPS-I) while its second product, Naglazyme, is appoved for the treatment of MPS-VI. Recently, the company received FDA approval for its third product, Kuvan, for the treatment of PKU. Strong sales of Kuvan, coupled with accelerating sales of both Aludrazyme and Naglazyme, will drive the company to profitability in 2008 and beyond. As such, we maintain our Buy rating on the stock with a price target of $40...by Zacks Stock crossed MA(50) http://astuk-virtuallystocks.blogspot.com/
$36.4 (05/01/08)
